Chardan Capital analyst Daniil Gataulin maintained a Hold rating on Outlook Therapeutics (OTLK – Research Report) today and set a price target ...

Chardan Capital Markets has recently initiated Mind Medicine (MindMed) Inc (MNMD) stock to Buy rating, as announced on December 20, 2024, according to Finviz. Earlier, on October 14, 2024, Leerink ...

In a challenging market environment, DFLI, the stock for Chardan Nextech Acquisition 2, has reached a 52-week low, dipping to $2.49. According to InvestingPro analysis, the company's financial health ...

Fintel reports that on January 10, 2025, Chardan Capital initiated coverage of Unity Biotechnology (NasdaqGS:UBX) with a Buy ...

Chardan analyst Geulah Livshits downgraded Editas Medicine (EDIT) to Neutral from Buy and withdrew the firm’s price target after the company announced a strategic transition to focus entirely on ...

Eyenovia (EYEN) has engaged Chardan as its financial advisor in connection with its evaluation of strategic alternatives. With assistance from ...

Chardan initiated coverage of Stoke Therapeutics (STOK) with a Buy rating and $24 price target The firm cites the potential of the company’s lead asset zorevunersen for the treatment of Dravet ...

Outlook Therapeutics Inc (OTLK) stock saw a modest uptick, ending the day at $2.23 which represents a slight increase of $0.04 or 1.83% from the prior close of $2.19. The stock opened at $2.19 and ...

Chardan Capital reaffirmed their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a report released on Thursday,Benzinga reports. Chardan Capital currently has a ...

Eyenovia said it hired Chardan as its financial adviser as it goes through a business review that includes a potential sale of the company.

Dyne Therapeutics (NASDAQ:DYN – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at Chardan Capital in a research report issued on Friday,Benzinga reports. They presently ...